Works matching IS 02780232 AND DT 2021 AND VI 39

Results: 534
    1
    2
    3
    4
    5
    6
    7
    8
    9

    COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 712, doi. 10.1002/hon.2916
    By:
    • Del Poeta, Giovanni;
    • Bomben, Riccardo;
    • Polesel, Jerry;
    • Rossi, Francesca Maria;
    • Pozzo, Federico;
    • Zaina, Eva;
    • Cattarossi, Ilaria;
    • Varaschin, Paola;
    • Nanni, Paola;
    • Boschian Boschin, Romina;
    • Postorino, Massimiliano;
    • Laureana, Roberta;
    • Pasqualone, Gianmario;
    • Steffan, Agostino;
    • Gentile, Massimo;
    • Zucchetto, Antonella;
    • Gattei, Valter
    Publication type:
    Article
    10
    11
    12

    Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 570, doi. 10.1002/hon.2899
    By:
    • Cuneo, Antonio;
    • Rigolin, Gian Matteo;
    • Coscia, Marta;
    • Quaresmini, Giulia;
    • Scarfò, Lydia;
    • Mauro, Francesca Romana;
    • Motta, Marina;
    • Quaglia, Francesca Maria;
    • Trentin, Livio;
    • Ferrario, Andrea;
    • Laurenti, Luca;
    • Reda, Gianluigi;
    • Ferrari, Angela;
    • Pietrasanta, Daniela;
    • Sportoletti, Paolo;
    • Re, Francesca;
    • De Paoli, Lorenzo;
    • Foglietta, Myriam;
    • Giordano, Annamaria;
    • Marchetti, Monia
    Publication type:
    Article
    13

    Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 687, doi. 10.1002/hon.2914
    By:
    • Mesegué, Montserrat;
    • Alonso‐Saladrigues, Anna;
    • Pérez‐Jaume, Sara;
    • Comes‐Escoda, Ariadna;
    • Dapena, José Luís;
    • Faura, Anna;
    • Conde, Nuria;
    • Català, Albert;
    • Ruiz‐Llobet, Anna;
    • Zapico‐Muñiz, Edgar;
    • Camós, Mireia;
    • Rives, Susana
    Publication type:
    Article
    14

    Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 658, doi. 10.1002/hon.2919
    By:
    • Kraft, Robert M.;
    • Ansell, Stephen M.;
    • Villasboas, Jose C.;
    • Bennani, N. Nora;
    • Wang, Yucai;
    • Habermann, Thomas M.;
    • Thanarajasingam, Gita;
    • Lester, Scott C.;
    • Macon, William;
    • Inwards, David J.;
    • Porrata, Luis F.;
    • Micallef, Ivana N.;
    • Witzig, Thomas E.;
    • Thompson, Carrie A.;
    • Johnston, Patrick B.;
    • Nowakowski, Grzegorz S.;
    • Lin, Yi;
    • Paludo, Jonas
    Publication type:
    Article
    15

    Issue Information.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 593, doi. 10.1002/hon.2749
    Publication type:
    Article
    16
    17

    IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 707, doi. 10.1002/hon.2915
    By:
    • Benatti, Stefania;
    • Atene, Claudio Giacinto;
    • Fiorcari, Stefania;
    • Mesini, Nicolò;
    • Martinelli, Silvia;
    • Zucchini, Patrizia;
    • Bacchelli, Francesca;
    • Maccaferri, Monica;
    • Debbia, Giulia;
    • Potenza, Leonardo;
    • Rossi, Davide;
    • Vallisa, Daniele;
    • Trentin, Livio;
    • Gaidano, Gianluca;
    • Luppi, Mario;
    • Marasca, Roberto;
    • Maffei, Rossana
    Publication type:
    Article
    18
    19

    Is race important in genomic classification of hematological neoplasms?

    Published in:
    Hematological Oncology, 2021, v. 39, n. 5, p. 728, doi. 10.1002/hon.2909
    By:
    • Huang, Huijun;
    • Wu, Junying;
    • Qin, Tiejun;
    • Xu, Zefeng;
    • Qu, Shiqiang;
    • Pan, Lijuan;
    • Cai, Wenyu;
    • Liu, Jinqin;
    • Wang, Huijun;
    • Sun, Qi;
    • Jiao, Meng;
    • Gao, Qingyan;
    • Huang, Gang;
    • Gale, Robert Peter;
    • Li, Bing;
    • Xiao, Zhijian
    Publication type:
    Article
    20
    21

    Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 521, doi. 10.1002/hon.2906
    By:
    • Højholt, Karen Louise;
    • Gregersen, Henrik;
    • Szabo, Agoston Gyula;
    • Klausen, Tobias Wirenfeldt;
    • Levring, Mette Bøegh;
    • Preiss, Birgitte;
    • Helleberg, Carsten;
    • Breinholt, Marie Fredslund;
    • Hermansen, Emil;
    • Rahbek Gjerdrum, Lise Mette;
    • Bønløkke, Søren Thorgaard;
    • Nielsen, Katrine;
    • Kjeldsen, Eigil;
    • Iversen, Katrine Fladeland;
    • Teodorescu, Elena Manuela;
    • Kurt, Eva;
    • Strandholdt, Casper;
    • Andersen, Mette Klarskov;
    • Vangsted, Annette Juul
    Publication type:
    Article
    22
    23
    24

    Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 529, doi. 10.1002/hon.2910
    By:
    • Ribera, Josep‐Maria;
    • Morgades, Mireia;
    • Genescà, Eulàlia;
    • Chapchap, Eduardo‐Cerello;
    • Montesinos, Pau;
    • Acuña‐Cruz, Evelyn;
    • Gil, Cristina;
    • García‐Cadenas, Irene;
    • Barba, Pere;
    • González‐Campos, José;
    • Queipo de Llano, María‐Paz;
    • Torrent, Anna;
    • Ribera, Jordi;
    • Granada, Isabel;
    • Bernal, Teresa;
    • Díaz‐Beyá, Marina;
    • Amigo, María‐Luz;
    • Coll, Rosa;
    • Tormo, Mar;
    • Vall‐llovera, Ferran
    Publication type:
    Article
    25
    26
    27
    28

    Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 558, doi. 10.1002/hon.2898
    By:
    • Passamonti, Francesco;
    • Gupta, Vikas;
    • Martino, Bruno;
    • Foltz, Lynda;
    • Zaritskey, Andrey;
    • Al‐Ali, Haifa Kathrin;
    • Tavares, Renato;
    • Maffioli, Margherita;
    • Raanani, Pia;
    • Giraldo, Pilar;
    • Griesshammer, Martin;
    • Guglielmelli, Paola;
    • Bouard, Catherine;
    • Paley, Carole;
    • Tiwari, Ranjan;
    • Vannucchi, Alessandro M.
    Publication type:
    Article
    29

    Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 473, doi. 10.1002/hon.2902
    By:
    • D'Angelo, Christopher R.;
    • Hanel, Walter;
    • Chen, Yi;
    • Yu, Menggang;
    • Yang, David;
    • Guo, Ling;
    • Karmali, Reem;
    • Burkart, Madelyn;
    • Ciccosanti, Colleen;
    • David, Kevin;
    • Risch, Zachary;
    • Murga‐Zamalloa, Carlos;
    • Devata, Sumana;
    • Wilcox, Ryan;
    • Savani, Malvi;
    • Courville, Elizabeth L.;
    • Bachanova, Veronika;
    • Rabinovich, Emma;
    • Peace, David;
    • Osman, Fauzia
    Publication type:
    Article
    30
    31
    32

    Erratum.

    Published in:
    2021
    Publication type:
    Correction Notice
    33

    Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 498, doi. 10.1002/hon.2897
    By:
    • Akay, Olga Meltem;
    • Ozbalak, Murat;
    • Pehlivan, Mustafa;
    • Yildiz, Birol;
    • Uzay, Ant;
    • Yigenoglu, Tugce Nur;
    • Elverdi, Tugrul;
    • Kaynar, Leylagul;
    • Ayyildiz, Orhan;
    • Yonal Hindilerden, Ipek;
    • Goksoy, Hasan Sami;
    • Izmir Guner, Sebnem;
    • Gunes, Ahmet Kursad;
    • Sonmez, Mehmet;
    • Kurt Yuksel, Meltem;
    • Civriz Bozdag, Sinem;
    • Ozkurt, Zubeyde Nur;
    • Toptas, Tayfur;
    • Dogu, Mehmet Hilmi;
    • Salim, Ozan
    Publication type:
    Article
    34

    Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 580, doi. 10.1002/hon.2886
    By:
    • Papayannidis, Cristina;
    • Sartor, Chiara;
    • Dominietto, Alida;
    • Zappone, Elisabetta;
    • Arpinati, Mario;
    • Marconi, Giovanni;
    • Cristiano, Gianluca;
    • Nanni, Jacopo;
    • Parisi, Sarah;
    • Barbato, Francesco;
    • Paolini, Stefania;
    • Soverini, Simona;
    • Terragna, Carolina;
    • Robustelli, Valentina;
    • Testoni, Nicoletta;
    • Chirumbolo, Gabriella;
    • Curti, Antonio;
    • Cavo, Michele;
    • Bonifazi, Francesca
    Publication type:
    Article
    35
    36
    37

    Issue Information.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 437, doi. 10.1002/hon.2748
    Publication type:
    Article
    38
    39

    Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 3, p. 326, doi. 10.1002/hon.2861
    By:
    • Rigolin, Gian Matteo;
    • Cavazzini, Francesco;
    • Piciocchi, Alfonso;
    • Arena, Valentina;
    • Visentin, Andrea;
    • Reda, Gianluigi;
    • Zamprogna, Giulia;
    • Cibien, Francesca;
    • Vitagliano, Orsola;
    • Coscia, Marta;
    • Farina, Lucia;
    • Gaidano, Gianluca;
    • Murru, Roberta;
    • Varettoni, Marzia;
    • Paolini, Rossella;
    • Sportoletti, Paolo;
    • Pietrasanta, Daniela;
    • Molinari, Anna Lia;
    • Quaglia, Francesca M.;
    • Laurenti, Luca
    Publication type:
    Article
    40

    Mesenchymal stem cells enhance the impact of KIR receptor‐ligand mismatching on acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia

    Published in:
    Hematological Oncology, 2021, v. 39, n. 3, p. 380, doi. 10.1002/hon.2867
    By:
    • Zhang, Yu;
    • Zheng, Hao;
    • Ren, Jinhua;
    • Luo, Xiaofeng;
    • Zheng, Zhihong;
    • Zheng, Jing;
    • Zheng, Xiaoyun;
    • Chen, Yi;
    • Chen, Zhizhe;
    • Hu, Jianda;
    • Yang, Ting
    Publication type:
    Article
    41

    Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 3, p. 401, doi. 10.1002/hon.2851
    By:
    • Latagliata, Roberto;
    • Attolico, Immacolata;
    • Trawinska, Malgorzata Monika;
    • Capodanno, Isabella;
    • Annunziata, Mario;
    • Elena, Chiara;
    • Luciano, Luigiana;
    • Crugnola, Monica;
    • Bergamaschi, Micaela;
    • Bonifacio, Massimiliano;
    • Baratè, Claudia;
    • Mauro, Endri;
    • Binotto, Gianni;
    • Sgherza, Nicola;
    • Aguzzi, Chiara;
    • Monteleone, Barbara;
    • Sorà, Federica;
    • Caocci, Giovanni;
    • Luzi, Debora;
    • Mariggiò, Elena
    Publication type:
    Article
    42
    43
    44

    Long‐term follow‐up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 4, p. 506, doi. 10.1002/hon.2835
    By:
    • Núñez‐García, Beatriz;
    • Rodríguez‐Pertierra, Marta;
    • Sequero, Silvia;
    • Carvajal, Laura G.;
    • Ruano‐Ravina, Alberto;
    • Aguiar, David;
    • Gumá, Josep;
    • Blanco, Cristina Q.;
    • García Arroyo, Francisco R.;
    • Garitaonaindia, Yago;
    • Provencio, Zaida;
    • Calvo, Virginia;
    • González‐San Segundo, Carmen;
    • Provencio, Mariano
    Publication type:
    Article
    45
    46

    Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 3, p. 293, doi. 10.1002/hon.2864
    By:
    • Genuardi, Elisa;
    • Klous, Petra;
    • Mantoan, Barbara;
    • Drandi, Daniela;
    • Ferrante, Martina;
    • Cavallo, Federica;
    • Alessandria, Beatrice;
    • Dogliotti, Irene;
    • Grimaldi, Daniele;
    • Ragaini, Simone;
    • Clerico, Michele;
    • Lo Schirico, Mariella;
    • Saraci, Elona;
    • Yilmaz, Mehmet;
    • Zaccaria, Gian Maria;
    • Cortelazzo, Sergio;
    • Vitolo, Umberto;
    • Luminari, Stefano;
    • Federico, Massimo;
    • Boccadoro, Mario
    Publication type:
    Article
    47

    Erratum.

    Published in:
    2021
    Publication type:
    Correction Notice
    48
    49
    50

    Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma.

    Published in:
    Hematological Oncology, 2021, v. 39, n. 3, p. 349, doi. 10.1002/hon.2863
    By:
    • Takakuwa, Teruhito;
    • Ohta, Kensuke;
    • Nakatani, Eiji;
    • Ito, Tomoki;
    • Kaneko, Hitomi;
    • Fuchida, Shin‐Ichi;
    • Shimura, Yuji;
    • Yagi, Hideo;
    • Shibayama, Hirohiko;
    • Kanda, Junya;
    • Uchiyama, Hitoji;
    • Kosugi, Satoru;
    • Tanaka, Hirokazu;
    • Kawata, Eri;
    • Uoshima, Nobuhiko;
    • Ishikawa, Jun;
    • Shibano, Masaru;
    • Karasuno, Takahiro;
    • Shindo, Maki;
    • Shimizu, Yoshifumi
    Publication type:
    Article